US · Healthcare · Diagnostics & Research
EPS came in at 4.27 against a street estimate of 3.95 — a beat of 8.1%.
Analysts rate IDEXX Laboratories Inc a buy (8 buy, 5 hold, 1 sell out of 14) with an average price target of $705.50.
CONFIDENT IDEXX beat Q2 expectations with 9% organic growth, raised full-year guidance, and demonstrated strong execution across diagnostics. Innovation momentum (inVue Dx, Cancer Dx) and international expansion offset U.S. visit declines. Q2 2026 International sustaining double-digit CAG Diagnostics recurring growth led by volume. IDEXX expanding field presence in 4 international countries plus targeted U.S. additions. Analysts pressed on FNA uptake (management confident, expanding Q3), lab growth drivers despite wellness declines (Cancer Dx + competitive wins), commercial investment ROI (proven playbook), and margin phasing (Q3 modest expansion, 2H investments). Management emphasized innovation breadth, customer loyalty, and international sector development opportunity. Little pushback on guidance; focused debate on visit trends sustainability and margin bridge. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.37% |
| Vanguard Capital Management, LLC | 6.54% |
| Vanguard Portfolio Management, LLC | 4.95% |
| State Street Corp | 4.76% |
| Amvescap Plc. | 4.58% |
| Geode Capital Management, LLC | 3.25% |
| BAMCO Inc | 2.51% |
| Morgan Stanley - Brokerage Accounts | 1.72% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 IDEXX LABORATORIES, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6 months): $2,357.4 million, up from $2,107.9 million (2025); Q2 R | 2026-08-04 |
| Results announced · Q3 2026 IDEXX LABORATORIES Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $1,217 million, up 10% reported and 9% organic • Q2 2026 diluted EPS | 2026-08-04 |
| Charter / bylaws change · Q2 2026 IDEXX LABORATORIES INC - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 12, 2026 • Three Class II directors elected: Daniel | 2026-05-15 |
| Quarterly report · Q1 2026 IDEXX LABORATORIES, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Total Revenue Q1 2026: $1,140.8 million (+14.3% vs Q1 2025: $998.4 million) | 2026-05-05 |
| Results announced · Q2 2026 IDEXX LABORATORIES Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 revenue: $1,141 million, up 14% as reported and 11% organic year-over-year • | 2026-05-05 |
| Proxy statement · Q4 2025 IDEXX LABORATORIES, INC. – 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION & CHANGE • Jonathan J. Mazelsky's 2025 Total Compensation: Not explicitly s | 2026-03-27 |
| Board / officer change · Q1 2026 IDEXX LABORATORIES, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Executive separation costs totaling approximately $2,280,000 in cash payouts - Sala | 2026-03-26 |
| Annual report FY2025 IDEXX LABORATORIES, INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization as of June 30, 2025: $42.9 billion • Shar | 2026-02-20 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for IDEXX Laboratories Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.